ER intrabody-mediated inhibition of interferon α secretion by mouse macrophages and dendritic cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
10
2018
accepted:
26
03
2019
entrez:
17
4
2019
pubmed:
17
4
2019
medline:
28
12
2019
Statut:
epublish
Résumé
Interferon α (IFNα) counteracts viral infections by activating various IFNα-stimulated genes (ISGs). These genes encode proteins that block viral transport into the host cell and inhibit viral replication, gene transcription and translation. Due to the existence of 14 different, highly homologous isoforms of mouse IFNα, an IFNα knockout mouse has not yet been established by genetic knockout strategies. An scFv intrabody for holding back IFNα isoforms in the endoplasmic reticulum (ER) and thus counteracting IFNα secretion is reported. The intrabody was constructed from the variable domains of the anti-mouse IFNα rat monoclonal antibody 4EA1 recognizing the 5 isoforms IFNα1, IFNα2, IFNα4, IFNα5, IFNα6. A soluble form of the intrabody had a KD of 39 nM to IFNα4. It could be demonstrated that the anti-IFNα intrabody inhibits clearly recombinant IFNα4 secretion by HEK293T cells. In addition, the secretion of IFNα4 was effectively inhibited in stably transfected intrabody expressing RAW 264.7 macrophages and dendritic D1 cells. Colocalization of the intrabody with IFNα4 and the ER marker calnexin in HEK293T cells indicated complex formation of intrabody and IFNα4 inside the ER. Intracellular binding of intrabody and antigen was confirmed by co-immunoprecipitation. Complexes of endogenous IFNα and intrabody could be visualized in the ER of Poly (I:C) stimulated RAW 264.7 macrophages and D1 dendritic cells. Infection of macrophages and dendritic cells with the vesicular stomatitis virus VSV-AV2 is attenuated by IFNα and IFNβ. The intrabody increased virus proliferation in RAW 264.7 macrophages and D1 dendritic cells under IFNβ-neutralizing conditions. To analyze if all IFNα isoforms are recognized by the intrabody was not in the focus of this study. Provided that binding of the intrabody to all isoforms was confirmed, the establishment of transgenic intrabody mice would be promising for studying the function of IFNα during viral infection and autoimmune diseases.
Identifiants
pubmed: 30990863
doi: 10.1371/journal.pone.0215062
pii: PONE-D-18-28638
pmc: PMC6467385
doi:
Substances chimiques
Interferon-alpha
0
Single-Chain Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0215062Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Genomics. 2004 Aug;84(2):331-45
pubmed: 15233997
Nat Commun. 2014 May 21;5:3864
pubmed: 24844667
Front Immunol. 2013 Oct 02;4:306
pubmed: 24106491
Vaccine. 2007 Feb 26;25(10):1856-67
pubmed: 17240000
Protein Sci. 2015 Sep;24(9):1440-50
pubmed: 26099203
PLoS Pathog. 2012;8(8):e1002868
pubmed: 22912583
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
J Immunol. 2010 May 1;184(9):5179-85
pubmed: 20308629
BMC Biotechnol. 2013 Jun 26;13:52
pubmed: 23802841
Trends Immunol. 2017 Aug;38(8):542-557
pubmed: 28579323
Gene. 2006 May 10;372:153-61
pubmed: 16488559
Gastroenterology. 2010 May;138(5):1885-97
pubmed: 20334827
J Virol. 2004 Aug;78(15):8219-28
pubmed: 15254193
BMC Biotechnol. 2017 May 12;17(1):42
pubmed: 28499450
Front Immunol. 2017 Aug 18;8:1001
pubmed: 28868054
Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):21-4
pubmed: 27586799
Protein Sci. 2017 May;26(5):925-945
pubmed: 28271570
J Interferon Cytokine Res. 2011 Apr;31(4):345-9
pubmed: 21138377
Biotechnol Bioeng. 2011 Nov;108(11):2670-81
pubmed: 21618470
PLoS One. 2013 Aug 05;8(8):e72700
pubmed: 23940817
Immunol Rev. 2004 Dec;202:8-32
pubmed: 15546383
Breast Cancer Res Treat. 1996;38(1):11-7
pubmed: 8825118
Nucleic Acids Res. 2002 Jan 15;30(2):E9
pubmed: 11788735
J Leukoc Biol. 1999 Aug;66(2):263-7
pubmed: 10449164
Gastroenterology. 2011 Oct;141(4):1231-9, 1239.e1-2
pubmed: 21741920
Nat Rev Immunol. 2015 Aug;15(8):471-85
pubmed: 26160613
PLoS One. 2013 Jul 17;8(7):e68674
pubmed: 23874717
Hum Mol Genet. 2015 May 1;24(9):2492-507
pubmed: 25601851
Annu Rev Immunol. 2011;29:163-83
pubmed: 21219184
J Immunol Methods. 1994 Sep 30;175(1):89-95
pubmed: 7930642
Protein Cell. 2018 Jan;9(1):3-14
pubmed: 28271446
Methods Mol Biol. 2012;907:59-71
pubmed: 22907345
Int Immunopharmacol. 2011 Jul;11(7):794-801
pubmed: 21281752
F1000Res. 2016 Aug 10;5:
pubmed: 27547383
MAbs. 2014;6(6):1394-401
pubmed: 25484057
Curr Protoc Immunol. 2011 Feb;Chapter 14:Unit14.21.1-11
pubmed: 21400681
Transplantation. 1999 Dec 27;68(12):1903-9
pubmed: 10628772
Genet Anal. 1999 Nov;15(3-5):161-5
pubmed: 10596757
Eur J Immunol. 2009 Jan;39(1):136-46
pubmed: 19130550
J Biotechnol. 2010 Jun;147(3-4):180-5
pubmed: 20430058
Cell Mol Biol Lett. 2013 Sep;18(3):433-46
pubmed: 23893288
Br J Pharmacol. 2013 Mar;168(5):1048-58
pubmed: 23072338
J Cell Mol Med. 2007 Jan-Feb;11(1):54-70
pubmed: 17367501
J Interferon Cytokine Res. 2002 Jun;22(6):653-9
pubmed: 12162875
Hum Gene Ther. 2002 May 1;13(7):803-13
pubmed: 11975847
JAKSTAT. 2013 Jan 1;2(1):e23820
pubmed: 24058799
MAbs. 2015;7(6):1010-35
pubmed: 26252565
Adv Exp Med Biol. 2016;917:77-93
pubmed: 27236553
Proc Natl Acad Sci U S A. 1995 May 9;92(10):4477-81
pubmed: 7753828
Cytokine. 2011 Nov;56(2):282-9
pubmed: 21856167
PLoS One. 2012;7(1):e30684
pubmed: 22292018
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472
Oncotarget. 2017 Jul 25;8(41):71249-71284
pubmed: 29050360
Pharm World Sci. 2005 Dec;27(6):423-31
pubmed: 16341948
J Exp Med. 1997 Jan 20;185(2):317-28
pubmed: 9016880
BMC Biotechnol. 2010 Apr 13;10:31
pubmed: 20388199